Abstract Objective Drug-coated balloons (DCBs) may increase durability of endovascular
treatment of superficial femoral artery (SFA) disease while avoiding stent-related risks. The …

Objectives To assess the safety and effectiveness of the Stellarex™ drug‐coated
angioplasty balloon (DCB) to inhibit restenosis in the superficial femoral and/or popliteal …

Objectives: The hypothesis that paclitaxel-eluting balloon angioplasty provides higher 1-
year patency rates in femoropopliteal artery in-stent restenosis compared with standard …

Objectives: The purpose of this study was to evaluate the 5-year follow-up (FU) data of the
THUNDER (Local Taxan With Short Time Contact for Reduction of Restenosis in Distal …

Background Because stent implantation for disease of the superficial femoral artery has
been associated with high rates of late clinical failure, percutaneous transluminal …

Background—Peripheral percutaneous transluminal angioplasty is fraught with a substantial
risk of restenosis and reintervention. A drug-eluting balloon (DEB) based on a novel coating …

Purpose To test the ability of a drug-eluting balloon (DEB) to reduce recurrent in-stent
restenosis (ISR) in diabetic patients with femoropopliteal stents. Methods A prospective all …

Background: Atherosclerosis in the superficial femoral artery is common in patients suffering
from peripheral artery disease. Paclitaxel-eluting balloon (PEB) angioplasty, stenting, and …

Background: Transradial access reduces the incidence of access site complications of
percutaneous revascularization procedures. However, in patients with peripheral vascular …

Background Stents are placed in the femoropopliteal arteries for numerous reasons, such as
atherosclerotic disease, the need for dissection, and perforation of the arteries, and can …